Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | KDM6B | O15054 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27230891 | 1.00 | KDM4C (0.37) | KDM4CHTR1ABRD4CREBBPLRRK2 | |
| SCHEMBL27214614 | 1.00 | KDM4C (0.37) | KDM4CHTR1ABRD4CREBBPLRRK2 | |
| SCHEMBL27214577 | 0.87 | KDM4C (0.43) | KDM4CKDM6BMAPK1 | |
| SCHEMBL27214646 | 0.87 | KDM4C (0.43) | KDM4CKDM6BMAPK1 | |
| SCHEMBL27230942 | 0.87 | KDM4C (0.43) | KDM4CKDM6BMAPK1 | |
| SCHEMBL27214618 | 0.86 | BRD4 (0.36) | KDM4CBRD4CREBBPLRRK2MAPK1 | |
| SCHEMBL27214615 | 0.86 | BRD4 (0.36) | KDM4CBRD4CREBBPLRRK2MAPK1 | |
| SCHEMBL27230897 | 0.86 | BRD4 (0.36) | KDM4CBRD4CREBBPLRRK2MAPK1 | |
| SCHEMBL30782844 | 0.85 | KDM4C (0.38) | KDM4CHTR1AKDM6BP2RX7 | |
| SCHEMBL30782834 | 0.85 | KDM4C (0.38) | KDM4CHTR1AKDM6BP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2022217232-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | TAAR1, HTR1A, HTR1F | KDM4C 3293/4885HTR1A 2/4885BRD4 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.